Home
NewsNewsFlora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world's leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue's community of over 100 million members gains early exposure to proactive fertility financial planning.
Flora Fertility (FLORA), the first individually owned fertility insurance platform, has announced a partnership with Clue, the women-led, science-driven period and cycle tracking app trusted by more than 100 million people worldwide. The Flora Clue fertility partnership brings together two distinct but complementary parts of the same challenge: understanding reproductive health and being financially prepared to act on it.
The timing is deliberate. Women are thinking about fertility long before they are ready to have children, but the education, tools and financial structures that exist to support them have historically arrived only after a problem has already been identified. The partnership is designed to shift that dynamic, reaching women earlier and giving them both the knowledge and the infrastructure to plan ahead.
The practical structure of the collaboration works in both directions. Clue will introduce its global community to FLORA's proactive approach to fertility insurance, giving members a pathway from reproductive health awareness to financial preparedness. At the same time, new and existing FLORA policyholders will receive complimentary access to Clue Plus, the app's premium subscription tier, which includes advanced cycle insights, predictions, and pattern analysis.
Together, the two offerings give users something that has not previously existed as a combined product: up to $50,000 in future fertility coverage through FLORA, paired with the premium cycle intelligence that Clue Plus provides, accessible from a single relationship with both platforms.
The scale of the unmet need behind this collaboration is reflected in the numbers.
Clue already helps more than 100 million people worldwide understand their cycles. FLORA brings financial infrastructure, policies starting at $15 per month, backed by A-rated insurance partners and a global reinsurance panel, covering the full spectrum of fertility treatment from diagnostics and medications through IUI and IVF.
Most women are educated about how to prevent pregnancy but receive little structured guidance about how fertility changes over time or what building a family later in life may actually require, medically or financially. The Flora Clue fertility partnership is built around the argument that education and financial preparation should not arrive only when someone is already in difficulty.
Dr. Christy Lane, co-founder and Co-CEO of Flora Fertility, set out the core logic:
"Clue has created a trusted space where women are already learning about their bodies and taking a more active role in their health. By bringing FLORA into that experience, we can help women turn what they are learning into a plan for the future. Clue provides the insights to understand their reproductive health, while FLORA gives them a way to prepare financially for fertility care they may need later."
South Korea's infertility treatment support budget at the local government level has risen 149.6%, from 67 billion won in 2021 to 167.2 billion won in 2025. As the central government continues expanding eligibility and benefits, municipalities are calling for the programme to return to national funding, warning of growing regional disparities.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
